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Executive Summary 
 
This final report of the Lancet Commission into Liver Disease in the UK stresses the continuing increase in disease 
burden of liver disease from excess alcohol consumption and obesity, with high levels of hospital admissions and 
a worsening in deprived areas. It concludes that only with comprehensive food and alcohol strategies based on 
fiscal and regulatory measures including the Minimum Unit Price (MUP) for alcohol and the alcohol duty 
escalator, as well as an extension of the sugar levy on food content which has been proven by previous experience 
in this country, can the disease burden be curtailed.  Further evidence of the value of MUP is shown by initial 
published results (1) of its introduction in Scotland showing an overall 3% reduction in consumption, with the 
major effect as predicted on heavy drinkers of low-cost alcohol products The major contribution of obesity and 
alcohol to the high rates of the ten most common cancers is also discussed. The measures outlined by the departing 
Chief Medical Officer, Dame Sally Davies, to combat rising levels of obesity – the highest of any country in the 
West – are described along with the estimated health costs. 
 
The latest audit analysis of unacceptable levels of mortality for severely ill patients with liver disease in District 
General Hospitals (DGHs)(2) indicates the need for developing a masterplan for improving hospital care and such 
a plan is proposed in this report based around specialist hospital centres linked to DGHs by Operational Delivery 
Networks (ODNs). It has received strong backing from the British Association for Study of the Liver (BASL) and 
British Society of Gastroenterology (BSG) but is held up at NHS England (NHSE). The value of day-case care 
bundles to reduce high hospital readmission rates with greater care in the community is described, along with 
examples of locally derived schemes for the early detection of disease and in particular schemes to allow general 
practitioners (GPs) to refer patients directly for elastography assessment. New funding arrangements for GPs will 
be required if these are to be taken up more widely around the country, as is recommended. 
 
A new ComRes poll, to be published in autumn 2019, shows an appalling lack of understanding of harm to health 
from lifestyle causes, with a poor knowledge of alcohol consumption and dietary guidelines. The Commission 
has serious doubts as to whether the initiatives described in the Prevention Green Paper(3), with the onus placed 
on the individual based on the use of information technology and the latest in behavioural science will be effective. 
The final section of the report raises questions of meaningful survival in paediatric liver disease where despite 
excellent overall survival results, there are high levels of cognitive impairment. 
 
In the Conclusion, a strong plea is made for greater coordination between the various official and non-official 
bodies that have expressed views on the unacceptable disease burden from liver disease in this country in 
presenting a single, strong voice to the higher echelons of Government. It is those making the final decisions and 
whom the Commission can only presume are not yet convinced of the need. 
 
Not included in the report are the continuing efforts to eradicate hepatitis C virus (HCV) infection based on the 
extension of treatment by the new antiviral drugs to previously unidentified patient groups. Hepatitis B Virus 
(HBV) infection is also not considered as the efficacy of the new potentially curative agents remains to be 
established in multi-centre clinical trials.  
 
 
Introduction 
Although in last year’s report we wrote optimistically of a gathering momentum and to some extent this has 
continued, this year’s report is mainly concerned with a series of ongoing failures in terms of the continuing.  
harmful effects on health resulting from lifestyle causes. The broadcaster Adrian Chiles, who had learnt of the 
dangers of heavy drinking before it was too late for him personally, has been powerful in advocacy and was 
instrumental in the BBC Panorama programme in June, directed at the lobbying power of the drinks industry and 
its influence on Government policy. Sadly, the past 12 months have seen no progress in Government instituting 
the regulatory and fiscal measures which are the only proven way of controlling overall alcohol consumption in a 
country. In the Government’s recently published Green Paper “Advancing Our Health: Prevention in the 
2020s”(3), although acknowledging the extraordinarily high levels of overweight and obesity in the population, 
the main concern appears to be in tackling childhood obesity and for adults with obesity, the main funding 
commitment was for diabetes. The UK has the highest rate of obesity of any major nation in Western Europe and 
the latest report by the OECD described the conditions fuelled by excess body weight as soaking up more than 
8% of health expenditure in the UK while cutting life expectancy by an average of 2·7 years(4). 
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Although NHSE has announced new funding for alcohol care teams in hospitals(5) with the highest levels of 
admissions due to alcohol dependency, with one in five patients in UK hospitals consuming alcohol at a harmful 
levels and one in ten alcohol dependant(3), many more hospitals will need to be included in the scheme.  
 
Not surprisingly, with the continuing rise in hospital admissions of severely ill liver disease patients, adequate 
care and facilities continue to lag behind and the mortality figures can only be described as unacceptable. Further 
work this year has gone into developing a hospital masterplan based on networks of DGHs linked with specialist 
liver centres. But as indicated in this section of the report, the proposals are held up awaiting endorsement by 
NHSE. Results are given in the report on the use of transient elastography by groups of GPs in screening for early 
liver disease, showing it to be worthwhile in terms of detecting previously undiagnosed cirrhosis cases at a stage 
when treatment measures can be effective.  The severe cuts in community alcohol and addiction services are likely 
to add to the difficulties here as a result of reductions in public health spending. 
 
A worrying new finding relates to occurrence of neurocognitive impairment in infants and children with liver 
disease, raising issues over meaningful life outcomes. Also new to the Commission’s work this year and described 
in detail is a ComRes poll on public awareness of liver disease. The one encouraging event in recent months was 
a National Institute for Health Research (NIHR) broad call for research projects of a translational nature in liver 
disease encompassing many of the recommendations that have been made by the Lancet Commission. 
 
Alarming Lack of Public Awareness: Results of the ComRes Poll 
Polling by ComRes between 24th and 27th May 2019 of 2,016 British adults aged >18years, exposed a lack of 
knowledge about liver disease. Participants were asked a series of factual statements that assessed their knowledge 
of the causes of liver diseases and other elements of it. Questions were reviewed by ComRes consultants, who 
ensured validity of facts and balance in the questions. 
Almost one third (32%) of respondents wrongly believed the burden and number of deaths caused by liver disease 
in the UK are falling year-on-year. Only one in ten (11%) can correctly identify all three main causes of liver 
disease, whilst a quarter (26%) mistakenly think smoking is one of them. 
 
89% correctly identify drinking harmful levels of alcohol as part of the official drinking guidelines, but wrongly 
identified the weekly limit for men and women as over 14 units as advised by the UK Chief Medical Officers. In 
addition, 61% of respondents consider it possible to drink higher than recommended levels of alcohol for years 
without noticing any apparent harm to their health. 57% of alcohol drinkers claim their current level of 
consumption has no impact on their health, whilst just a quarter (26%) recognise it has a negative impact. Only 
43% of respondents agreed that labels on alcoholic drinks currently contain enough information on the health 
risks for the public to make informed choices, emphasising the need for more accurate and comprehensive 
labelling of alcoholic beverages. 
 
Two in five (40%) British adults rightly identify obesity as one of the three main causes of liver disease which is 
lower than the level of knowledge about alcohol misuse as a key risk factor. To combat obesity, there is 
overwhelming public support for reducing the sugar content in foods (77%) and making healthy food and drinks 
cheaper than unhealthier ones (81%). 
 
These findings, showing a lack of public appreciation of health information, should be viewed in the context of 
other similar reports. 
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Figure 1: Summary of Key Findings of the ComRes survey  
 
BURDEN OF LIVER DISEASE  MAIN CAUSES OF LIVER DISEASE 
In the UK, the disease burden and deaths caused by liver 
disease are falling year-on-year: 
  
True: 32% 
False: 68% 
  
Which are the three main causes of liver disease?* 
  
Alcohol misuse: 89% 
Obesity: 40% 
Viral hepatitis: 35% 
All three above correctly selected: 11% 
Smoking: 26% 
  
*Based on prompted responses, including a range of other options 
included in the survey (not listed: inherited genetic factors, blockages 
to the gallbladder, lack of iron in the diet, sleep deprivation) 
  
MISCONCEPTIONS ABOUT ALCOHOL MISUSE 
“You can drink higher than recommended 
levels of alcohol for years without 
noticing any apparent harm to your 
health”: 
  
True: 61% (N.B. correct answer) 
False: 39% 
  
  
  
Estimated number of units per week 
as the official level for low-risk 
drinking according to the UK Chief 
Medical Officers’ guidance: 
  
14 units: 16% (N.B correct answer) 
More than 14 units: 13% 
Less than 14 units: 39% 
Do not know: 33%  
How, if at all, do you consider your current level 
of alcohol consumption to impact your health? 
Of those who drink alcohol (n=1,660) 
  
No impact: 57% 
Negative impact: 26% 
Positive impact: 14% 
 STEPS TO COMBAT ALCOHOL MISUSE AND OBESITY 
To what extent, if at all, do you support or oppose each of the 
following measures aimed at reducing obesity? 
 
“Reducing the sugar content in foods” 
  
Net support: 77% 
Net oppose: 8% 
Do not know: 4% 
  
Making healthy food and drinks cheaper than unhealthier 
ones: 
  
Net support: 81% 
Net oppose: 4% 
Do not know: 5% 
  
To what extent, if at all, do you agree or disagree with each of the 
following? 
 
“Labels on alcoholic drinks contain enough information on health risks 
for the public to make informed choices” 
 
Net agree: 43% 
Net disagree: 28% 
Neither agree nor disagree: 22% 
Do not know: 8% 
 
“More calorie information on labels of alcoholic drinks would help 
consumers make more informed choices” 
 
Net agree: 52% 
Net disagree: 20% 
Neither agree nor disagree: 23% 
Do not know: 5% 
 
ComRes interviewed 2016 British adults aged >18yrs online between 24th - 27th May 2019. Data were weighted 
by key demographics including age, gender, region and social grade in order to be representative of all British 
adults. ComRes is a member of the British Polling Council and abides by its rules. Full data tables are available 
from https://www.comresglobal.com/polls/foundation-for-liver-research-public-polling/(published online 
10.10.2019) 
 
Continuing High Alcohol Consumption and Disease Burden  
Data from the Office for National Statistics shows that in 2017, 57·0% adults aged 16 years and over drank alcohol 
in the week before being interviewed which equates to 29·2 million people in the UK (Figure 2). The recent 
Monitoring and Evaluating Scotland's Alcohol Strategy (MESAS) report(6) on the effects of introduction of MUP 
(at 50pence per unit), showed a 3% reduction in consumption in Scotland for 2018 against a 2% overall increase 
in alcohol sales in England(1) and  the  recently published, sophisticated modelling exercise on the immediate 
impact of MUP showed a reduction in weekly purchases of 9.5g of alcohol per gram of alcohol was associated 
with an increase in purchase price of 0.64% - higher in lower income households, targeting the heavy drinkers of 
cheap alcohol. The results of the first 12 months of MUP on disease severity and mortality are likely to be 
confirmatory and during the first 20 years the policy, it is estimated, will result in 2036 fewer deaths. 
 
 
 
Figure 2: Self-reported drinking habits in the week prior to interview, Great Britain 2005-17(7) 
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The study of Roberts et al across England and Wales from 2004 to 2012 (2) has reported mortality rates following 
acute admission of 23·4% for alcohol related liver disease and 35·4% for those with hepatic failure at 60 days 
after admission, seven times higher than following acute admissions with stroke and eight times higher than for 
acute myocardial infarction (MI). The early deaths were directly related to complications of liver disease. 
Mortality was significantly lower for patients seen by consultant hepatologists and gastroenterologists and for 
patients admitted to transplant centres or larger hospitals. At five years following admission, mortality was 61·8% 
with alcohol related  liver disease and 57·1% for hepatic failure.  Using the same methodology to extend the 
analysis from 2004 to 2017, Public Health England have shown that for England the very high 60 day mortality 
remains unchanged (Figure 3) 
 
 
Figure 3: Mortality rates following admission with alcohol related liver disease and hepatic failure 2004-
2017   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A recent meta-analysis(8) suggests that the true prevalence of alcohol-related conditions in NHS hospitals is 
approximately 20-30 times higher than the official government statistics (ie 24-36million per annum), most likely 
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due to an lack of training of staff in the NHS to identify, diagnose, treat and record the number of people with 
alcohol related conditions(8). 
 
Analysis of data from a large teaching hospital in the South of England showed no evidence of improvement in 
survival of cirrhosis admissions over the last 15 years (Figure 4), echoing the results of an older study which 
showed no improvement between 1959 and 1976 (9). In previous reports, we presented analysis of Dr Foster data 
showing that in-hospital mortality for liver disease is consistently falling year on year. But the fact that 
improvements in hospital care have not translated into improvements in long-term survival of cirrhosis patients is 
a sad reflection of overall current UK practice. The majority of patients with cirrhosis are not picked up in primary 
care but remain undiagnosed until the first admission to hospital with complications of cirrhosis. Around one third 
die within months of first presentation. The legacy system of arranging cirrhosis follow-up in secondary care is 
also not fit for purpose. The audit carried out in Southampton of follow-up in the cirrhosis cohort (Figure 4) where 
the hospital policy was to review every cirrhosis patient at six monthly intervals in order to arrange endoscopy 
and ultrasound surveillance, in compliance with NICE guidelines(10). found that of 3010 cirrhosis patients, 13% 
only had been seen in clinic within the last six months and 73% had not been seen for three years; 47% had never 
been seen at all. Only 37% had a record of liver ultrasound within the last year and 37% had not had an endoscopy 
within the last three years. Overall, 63% of patients diagnosed with cirrhosis were missing out, essentially identical 
findings to a similar audit performed 5 years earlier.  
 
Using research funding from British Liver Trust LOCATE project, a virtual liver clinic has been piloted over the 
last year and preliminary indications are that by using data-based recall, sharing care with GPs and establishing 
virtual clinics, care can be dramatically improved(11). Liver centres need to must urgently put into place a regular 
audit of the efficiency of their follow up procedures and make the appropriate changes to ensure equality of access. 
This is particularly important for patients with alcohol related liver disease and are still drinking who will DNA 
appointments if they have been dealt with insensitively by medical staff previously. A situation that can potentially 
be avoided when combined liver/alcohol follow up is arranged through an alcohol care team. Over the last year 
in a pilot project as part of the LOCATE study, hepatoma and varices screening for a subset of patients were 
arranged using a data system developed by Alan Hales via a virtual clinic(11). Preliminary indications are that 
this system is successful and extremely cost effective.   
 
 
Fig 4: Survival of patients following first admission with a diagnosis of cirrhosis categorised into three 
year cohorts 
 
 
Data was extracted from the 
Patient Administration System 
(PAS) at University Hospitals 
Southampton for consecutive 
admissions with a primary or 
secondary diagnosis of cirrhosis 
according to ICD 109 coding. 
Date of death is regularly updated 
to the PAS system from the 
national Mortality Tracing 
Service and enabled survivals to 
be calculated and a Kaplan Meier 
survival analysis to be performed. 
Data obtained from several other 
large UK liver centres previously 
is not presented but showed a 
similar picture. 
 
 
 
 
 
Alcohol Care Teams and 
Community Alcohol Services 
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The NHS long-term plan, published in January 2019(5), includes a commitment to establish and optimise alcohol 
care teams (ACTs) in district general hospitals over the next five years.  NHSE and NHS Improvement (NHSE&I) 
will be targeting the worst affected hospitals with additional monies(5). Funding is to come from the clinical 
commissioning groups’ health inequalities funding supplement, working in partnership with local authority 
commissioners of drug and alcohol services from 2020/21.In addition, a £4.5 million innovation fund was 
launched in 2018 by the Department of Health and Social Care for local projects working with children and 
families affected by alcohol(12). NHSE will apparently be providing guidance on implementation which is going 
to take, in the Commission’s view, considerable and detailed effort. Moriarty identifies eleven components as 
essential in ACTs (see Box 1)(13) and in a 2009 survey of ACTs in London hospitals, only 42% had an alcohol 
support nurse (ASN) and 10% a lead clinician(14);  in 2016, 83% of UK hospitals had ASNs(15), and in 2019, 
around 60% have a clinician lead although many hospitals are still not staffed to provide a 7-day ASN service. 
 
 Box 1:  Key components of Alcohol Care Teams(13) 
1. A clinician-led, multidisciplinary alcohol care team, with integrated alcohol treatment pathways across 
primary, secondary and community care; 
2. Coordinated alcohol policies for emergency departments and acute medical units; 
3. A 7-day alcohol specialist nurse service; 
4. Addiction and liaison psychiatry services; 
5. An alcohol assertive outreach team for frequent hospital attenders; 
6. Specialist consultant hepatologists and gastroenterologists with expertise in liver disease; 
7. Collaborative, multidisciplinary, person-centred care; 
8. Quality metrics, national indicators and audit; 
9. Workforce planning, training and accreditation; 
10. Research, education and health promotion for the public and healthcare professionals; 
11. Formal links with local authority, public health, clinical commissioning groups, patient groups, and other 
key stakeholders. 
 
The 9% of people in England with alcohol dependence account for 59% of all alcohol-attributable hospital 
admissions (16). Alcohol assertive outreach treatment (AAOT) for the estimated 54,369 patients in England with 
alcohol-attributable hospital admissions has an implementation cost of £161 million, with cost savings of around 
£575 million, the return on investment (ROI) being £3·42 for every £1 spent(17) and also strongly correlates with 
the index of multiple deprivation (r=0·74)(17). With the emphasis of the prevention Green Paper on reducing 
health inequalities, the Commission’s view is that ACTs and AAOT should be rolled out to all DGHs with a 
demonstrated patient burden of alcohol-related illness. This would facilitate achievement of the United Nations 
General Assembly Sustainable Development Goals (SDGs), especially SDG 10, which aim to reduce 
global health inequalities and provide a more equitable and sustainable future for all people by 2030. 
 
The alcohol and tobacco CQUIN (Commissioning for Quality and Innovation) was introduced in 2017 and is 
being implemented across all inpatients in mental health, community and secondary care NHS trusts(18). Latest 
data shows that overall, 25·2% of screened inpatients are drinking at increasing/higher risk/possible dependent 
levels in mental health trusts, 14·2% in acute trusts, and 6·4% in community trusts (personal communication). 
These figures are to be compared to 25% of the general population who are drinking at increasing and higher risk 
levels and dependence. 
 
Reduction in community treatment and addiction services 
Since the introduction of the Health and Social Care Act, combined with cuts to the government’s Public Health 
Grant to local authorities, there has been an 18% (£162million) reduction in funding to community addiction 
treatment services in England, with ten local authorities reducing by at least 40%(19)  resulting in a 22% reduction 
in the number entering specialist alcohol treatment, and a 52% reduction in access to specialist inpatient alcohol 
detoxification(19). England now has less than half the level of access to specialist alcohol treatment compared to 
Scotland and Wales (Table 1). 82% of people with alcohol dependence do not currently access specialist 
treatment(19). 
 
 
 
Table 1: Alcohol treatment access ratios across the United Kingdom 2017/18 compared to 2016/17 
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Country Number 
accessing 
treatment for 
alcohol only1 
Number of F10 
alcohol hospital 
admissions2 
Rate of F10 
admissions 
/100,000 
population >18 
years 
Treatment access 
ratio (F10 
admissions/ 
treatment access)3 
Treatment 
access ratio 
(20) 
Scotland 26,107 27,025 614·9 1·0 1·1 
Wales 7,678 8,804 307·5 1·1 1·2 
England 75,787 197,460 451·3 2·6 2·4 
Northern Ireland 2,577 9,963 694·6 3·9 3·9 
United Kingdom 112,149 243,252 467·0 2·2 2·1 
 
1Excludes concurrent drug misuse as a reason for treatment. 
2Primary or secondary diagnosis of ICD10 F10 ‘Mental and Behavioural Disorders due to Use of Alcohol’. This 
is a proxy measure of the prevalence of alcohol dependence in the general population. 
3Note the treatment access ratio - the number of F10 admissions to NHS hospitals divided by the number of people 
accessing specialist alcohol treatment –worsened in England and the UK as a whole. 
 
 
Another consequence of the cuts has been a 48% reduction in the number of NHS specialist addiction consultants 
in England, and a 60% reduction in the number of specialist addiction trainees(21).  
 
Public Health England (PHE) announced in March 2019 a £6 million capital fund to enable local authorities to 
invest in improving access to alcohol treatment services and of the 23 projects commissioned, seven comprised 
purchase of elastography machines to enable rapid identification of liver disease(22). 
 
Need for a Comprehensive Strategy to Reduce Alcohol Consumption 
Not only are alcohol related deaths rising(23) but the number of people harmed by someone else’s drinking is 
estimated at one-in-five according to a recent Public Health England (PHE) report(24). Much evidence is available 
of effective solutions that could be adopted, with action on price, availability and marketing at the top of the list 
of interventions (25). The 50pence minimum unit price (MUP) of alcohol it is estimated would reduce alcohol 
attributable deaths in England by 4·3% and associated healthcare costs by 2·3%(26). Strong consensus exists 
amongst health, social care, justice and civil society groups that such measures are urgently needed to tackle 
alcohol harm(27). A comprehensive alcohol strategy by Government should follow the recommendations of WHO 
and tackle the affordability, availability and promotion of alcohol, aiming for a 10% reduction in harmful use of 
alcohol by 2020(28).  
 
The UK Government has repeatedly failed to grasp many opportunities to take meaningful action to prevent 
alcohol harm. Plans for a UK alcohol strategy announced in May 2018(29) have been put on hold whilst the 
Chancellor of the Exchequer has made alcohol more affordable by cutting duty in the October Budget 2018(30) 
(a decision that resulted in a loss of £1billion to HM Treasury, equivalent to the annual salaries of 40,000 
nurses(31). A 2% above inflation increase in alcohol duty would result in 4,710 fewer alcohol related deaths and 
160,760 fewer hospital admissions between 2020-2035, according to the latest modelling report(32), as well as 
raising substantial funds to support over-stretched local public health budgets.  
 
The Government’s Prevention Green Paper(3), whilst acknowledging that alcohol harm is rising, made no 
commitment to address the major drivers of ill-health and inequality linked to alcohol(3), devoting only one and 
a half pages of the 78 page document to alcohol consumption. No actions were proposed to target the 4% of the 
adult population who are the heaviest drinkers that account for 30% of all alcohol consumed. The Department of 
Health and Social Care (DHSC) are to review the evidence for increasing the alcohol-free descriptor threshold 
from 0·05% ABV to 0·5% ABV(3). Such a move, however, will have no impact on the high-risk drinkers who 
are most in need of specialist treatment and support services.  
 
Another missed opportunity for Government to act in the interests of public health was the 1st September 2019 
deadline given to alcohol companies to display up to date and accurate information on product labels about the 
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health risks associated with alcohol(33). The majority of drinks sold do not carry the latest Chief Medical Officer’s 
low risk drinking guidelines, leaving consumers in the dark about the latest health advice(34). In August 2019, a 
month before the Government’s deadline to display the guidelines on labels, the alcohol industry’s Portman Group 
announced it was ‘encouraging’ its members to display the CMO advice on product labels(35) but no timelines 
were offered for implementation.. 
 
Disease Consequences of High Obesity Prevalence 
In 2017, the prevalence of obesity in adults was 29%, representing a 3% annual increase, whilst for children in 
Year 6 and Reception the figures were 20·1% and 9·5% respectively. Of particular concern is the increasing gap 
in obesity prevalence between the least and most deprived deciles, with a five percentage point increase for Year 
6 children between 2006/07 and 2017/18(36). Obesity related disorders remain a major contributor to hospital 
workload, with 10,660 admissions directly attributable to obesity and over 700,000 admissions where it is a 
primary or secondary diagnosis (a 15% annual increase). The 6,627 admissions for bariatric surgery in 2017/18 
are an increase of 2% over the previous year(36) but represent treatment of less than 2% of eligible individuals.   
The National Cardiovascular Intelligence Network (NCVIN) estimates that there are 4 million people with Type 
2 diabetes in England, of whom 2·9 million have been diagnosed with the condition(37). Obesity is estimated to 
be responsible for 80 to 85% of someone’s risk of developing Type 2 diabetes and the condition is responsible for 
more than 3000 amputations, over 19,000 strokes and almost 15,000 myocardial infarctions every year(38). At 
least 10,000 people in the UK have end stage renal failure as a consequence of their diabetes and more than 1,700 
have their sight seriously affected by their diabetes each year. Type 2 diabetes incurs almost £9 billion of costs to 
the NHS annually, around 9% of the total NHS budget (39). Of particular concern is the marked increased in 
prevalence in children and young adults, with 745 people under the age of 25yrs reported as having Type 2 
diabetes in England and Wales in 2017/18(40).  End-stage non-alcoholic fatty liver disease (NAFLD) is a growing 
clinical problem in the UK, placing major challenges on the NHS. In particular cases of NAFLD with 
decompensated cirrhosis are rising such that they are now also posing an increasing burden on transplant 
services(41).  
 
The Chief Medical Officer published a report in October that made clear the magnitude of the challenge of 
achieving the Government’s  ambition to halve child obesity by 2030 and  provided 49 wide-ranging 
recommendations designed to drive fundamental changes in the environments that shape our dietary and physical 
activity behaviours. This will involve much greater regulation of the food industry, major restrictions on 
advertising and marketing of unhealthy products and transformation of our towns and cities to create safe, 
appealing environments in which children can walk, cycle and play(42). The Department of Health and Social 
Care has proposed a number of actions(43, 44) in Chapter 2 of the Child Obesity Plan in 2018(45) including 
policies to reduce both total calorie consumption and sugar intake and to restrict advertising and marketing of 
unhealthy food to children. However, at the time of publication these were still under consultation and had not yet 
been implemented. The recently published Green Paper on Prevention(3) contains a range of proposals including 
labelling, food reformulation, weight management services and physical activity promotion but gives little 
guidance on how these will be translated into effective policies which will require much more intensive policy 
action than has been seen to date (46). The only new regulatory commitment was to consult on ending the sale of 
energy drinks to the under 16yrs age group.  
 
The persistent framing of obesity as merely the result of individual choice needs to be challenged. While decisions 
about both diet and physical activity are ultimately made by individuals, the ‘choices’ available to people depend 
on a wide variety of factors. Those behavioural decisions are primarily driven by environments that promote over-
consumption of food and under-expenditure of energy. It is only by tackling these obesogenic environments that 
equitable reductions in prevalence and consequent health benefits will be achieved and sustained. 
 
Marketing of Unhealthy Food and Alcohol  
There is unequivocal evidence that the marketing of unhealthy food to children leads to childhood obesity (47) 
and that marketing of alcohol leads to an uptake of drinking and increased consumption in young people (48). 
Similar evidence for the marketing of cigarettes and smoking in young people led to comprehensive and effective 
global bans on tobacco as part of the International Framework Convention on Tobacco Control (49). In contrast, 
the food and alcohol industries have been allowed to ‘self-regulate’ despite evidence that this does not effectively 
reduce childhood exposure to adverts (50). In an increasingly digital age - children aged 12-15yrs are online for 
an average of 21 hours each week in the UK (51) - teenagers are exposed to promotional activities which include 
paid-for advertisements, product placement, content sharing by peers or the activities of social media influencers. 
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These targeted messages are then narrowcast to mobile devices without parental control or oversight. Young 
people cannot always recognise these marketing tactics as having a commercial goal or distinguish them from 
organic(52). The spend on digital marketing has increased year on year, in 2016 receiving the largest share of 
advertising spending in the UK(53). 
 
Social media and other operators have created sophisticated datasets to target consumers but between the 
commercial operators with products to sell and their young target audience, marketing messages disappear into a 
black box marketplace where individual messages are sold on by a myriad of intermediate agencies – supply-side 
platforms, data exchanges and demand-side platforms - which bid for advert impressions (54). Though advertising 
messages could be tagged and traced, there is no facility to do this within the current marketplace. Effective forms 
of age verification do exist but these are not currently used to filter marketing traffic with the result that no one 
knows if a marketing message is seen by a child or an adult. 
 
Earlier this year the World Health Organisation published an outstanding report including pragmatic solutions 
(54), the CLICK tool providing the conceptual framework needed to understand and monitor exposure of children 
to digital messages(47). Along with estimating exposure, WHO suggest there should be effective age verification 
and message tagging, coupled to achieve effective regulatory regimes. Policy makers need to be made aware that 
the digital marketplace in the UK is almost entirely un-regulated and mandatory Government measures to reflect 
this unique environment are urgently needed.     
 
Obesity as Cause of Common Cancers 
Most cancer types have multiple risk factors but 38% of the 22,800 cancer cases annually in the UK are 
preventable(55) including 49% of liver cancer (around 2,800 cases). Overweight and obesity (body mass index 
[BMI] 25+) contribute the highest proportion of liver cancers (around 1,300 cases annually) and is second only to 
smoking as the leading preventable cause of cancer in the UK, with alcohol consumption ranking sixth(55). 
Overweight and obesity have a definite causal link with 13 cancer types, namely breast, bowel, oesophagus and 
kidney (high) liver, pancreas and uterus (moderate) and oral, ovary, myeloma and thyroid (low). Alcohol  
consumption is linked with seven cancer types(56, 57) with obesity having a synergistic effect and adding to the 
risk of breast, bowel, liver and oesophagus(58, 59). The other three – mouth, upper throat and larynx – having a 
specific and distinct association with excess drinking.  
  
View of Commission Members on the Government’s Prevention Green Paper (3) 
The comments of two members of the Commission are quoted in full as a reflection of the view of the Commission 
as a whole and of many comments by professional bodies and agencies beyond the scope of this report. The first 
is by Professor Martin McKee: “In July 2019 the Department of Health and Social Care finally, and very 
reluctantly, published its Green Paper on prevention Accounts from Whitehall insiders report how the Health 
Secretary  sought to withhold it and then when Theresa May, Prime Minister at the time, decided it should be 
published, sought to have the Department’s name removed.  Unusually, when it did appear, it was not 
accompanied by a press release. The widespread scepticism with which it was greeted(60) has been encouraged 
by news that the new Prime Minister has appointed advisers linked to lobby groups funded by manufacturers of 
harmful products(61). 
  
The section on alcohol begins by saying that “Most people who drink, do so responsibly”. A recent study examined 
how the concept of responsible drinking is almost exclusively used by the alcohol industry and groups it funds(62). 
Until now, this term very rarely appeared in government documents. That study also found that it was often used 
in a context where government guidelines were being undermined and where the alcohol industry was portrayed 
as pursuing corporate social responsibility. 
 
The government’s proposals are extremely weak and ignore the evidence favouring population-based measures, 
such as taxation, reductions in availability, and restrictions on marketing which, as shown in the previous Lancet 
Commission on Liver Disease, are all strongly opposed by the alcohol industry.(20) There are three main 
proposals. The first is to make people more aware of alcohol-induced harms through Public Health England’s 
One You campaign(63). The second is to stress the value of an alcohol risk assessment in the NHS Health Check, 
another initiative criticised for lacking evidence of effectiveness(64). The third is the support children with alcohol 
dependent parents although, surprisingly for a consultation document, this has already been launched, in April 
2018. A final section discusses collaboration with the alcohol industry to promote low alcohol products, without 
reference to the experience of the heavily criticised industry partnership in the Responsibility Deals, and in a 
major concession to the industry, promises to review the potential to redefine “alcohol free” to allow up to ten 
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times the current level of alcohol. In summary, this is a document that could easily have been written by the 
alcohol industry and is almost wholly devoid of a public health perspective.” 
  
The second comment is by Professor Harry Rutter: “The Government’s recent Prevention Green Paper is framed 
in terms of individual responsibility and personalised approaches, diverting focus away from the commercial and 
structural drivers of ill health in the population that so urgently need to be tackled. However, there are some 
positives including proposed actions on obesity which represent solid work by the DHSC and PHE obesity teams 
but it goes nowhere near far enough.”  
 
Planned Proposals to Improve Hospital Based Care   
The Hepatobiliary Clinical Reference Group (HPB CRG) which advises NHSE on the management of patients 
with advanced liver disease has made a number of recommendations for major changes in response to the 
increasing volume of patients with cirrhosis and variation in outcomes between providers. The complexity of 
managing patients with acute on chronic liver failure and decompensated cirrhosis requires an experienced, 
diverse clinical team with 24-hour care provided by specialist hepatologists supported by appropriately trained 
intensivists, radiologists, dieticians, nurses and pharmacists as well as ready access to liver transplantation 
services. Such services cannot be provided in every hospital which admits patients with cirrhosis and to ensure 
that all patients have equal access to high quality care, the CRG has recommended that regional networks are 
established with each hospital linked to a centrally supported specialist centre. The establishment of a 
comprehensive series of networks with appropriate funding and support and is strongly recommended by the 
Commission but as referred to earlier, the proposals continue to await endorsement by NHSE, with no date for 
implementation.  
 
To facilitate the development of the networks, the HPB CRG have recommended a new service specification for 
specialist providers of liver services which should lead to the development of a more targeted referral pathways. 
Patients with advanced liver disease admitted to any hospital in the country would receive early, algorithm based, 
review (including use of the well-established ‘cirrhosis care bundle’) followed by discussion with the local liver 
lead and, if appropriate, with the regional liver centre. An example of this working is in East London where a 
Barts Health NHS Trust hepatology consultant is based at Queens Hospital in Romford and provides out-patient 
and in-patient advice on specialist liver care for the region.  
 
To improve current provision of care for patients with decompensated cirrhosis, NHSE has offered a new incentive 
scheme (CQUIN) which rewards trusts who introduce network based approaches to the management of patients 
with cirrhosis (65). Monitoring and evaluation of the changes will be through a new ‘Cirrhosis Dashboard’(66) 
which provides information on a range of metrics relating to the quality of care for patients with liver disease and 
will be sent to trust chief executives every quarter. An analysis of data from the NHSE cirrhosis dashboard from 
June 2018 to April 2019 of the 40 trusts currently commissioned to provide specialist liver services, showed that 
a large number (over 120) are continuing to manage patients with cirrhosis although many report relatively small 
numbers of patients – 20 trusts admitted fewer than ten patients a quarter to HDU/ITU and 76 trusts admitted 
fewer than 20 such patients. 7·5% of the patients with decompensated liver disease admitted as an emergency 
died in hospital with a mortality of 8% in non-specialist trusts compared to 6·6% in commissioned, specialist 
centres.  
 
Emerging therapeutics (such as next generation anti-inflammatories for alcoholic hepatitis) and technologies 
(including the long-awaited development of ‘liver assist’ devices that deliver meaningful benefits) are likely to 
further enhance the differences in outcomes between the high and low volume centres.  
 
Opportunities to Improve Post-hospital Discharge Care  
Cirrhotic patients who survive an emergency admission to hospital with ascites are frequently readmitted within 
a month of discharge and while some readmissions are inevitable due to continued disease progression, many are 
potentially avoidable. An analysis of 120,000 cirrhosis admissions revealed ascites or hepatic encephalopathy 
(HE) to be the major predictors of unplanned readmission at 30 or 90 days(67). Readmissions are often attributable 
to patients’ insufficient understanding of their medications or early recognition of symptoms and both the 
American Association for Study of Liver Diseases (AASLD) and European Association for Study of the Liver 
(EASL) guidelines emphasise the importance of education (68). In one study, only 6% of HE patients and their 
carers understood the purpose of drug therapy or its side effects(69) and a survey of 150 cirrhosis patients found 
awareness of HE and its treatment was lower than for any other complication(70). The relatively simple 
intervention of providing educational booklets and structured post-discharge care needs to be more widely 
promoted by NHSE and adopted by hospital trusts. 
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Excellent results can be obtained by trained Nurse Specialists for large volume paracentesis (LVP) performed for 
diuretic refractory ascites as elective day-case procedures. In Cambridge, this has saved over 500 bed-days per 
year, at greater convenience for the patients. Nurse-led paracentesis is also offered in other locations, including 
Brighton, Bristol, Cardiff, Gloucester, London, Newcastle, Plymouth, Portsmouth, Southampton and Truro and 
should be included in planned care strategies for all hospitals treating liver patients. The value of this is further 
shown by a recent analysis of over 13,000 people with cirrhosis in their last year of life, with day-case services 
giving lower costs and a lower probability of patients dying in hospital (71). The use of paper-based or electronic 
decision support tools, prompting hospital staff to follow guidelines, has the potential to increase the proportion 
of patients discharged on appropriate medications, leading to fewer readmissions (67) and the comprehensive 
cirrhosis “discharge care bundle” now being piloted are other approaches meriting wider scale implementation.  
 
Failure to Increase Number of Liver Transplants 
The 1003 liver transplants in 2018-2019 (72) represent a reduction in activity compared with the 2017-18 total of 
1043. Disappointing also, with the potential for machine perfusion to increase the number of utilised organs, only 
8% (63) of adult deceased donor first liver transplants were reported to have involved normothermic or 
hypothermic machine perfusion, with no use of it in two of the centres. At the end of 2018-19 the waiting list had 
risen by 20% (432 from 359) and during 2016-17, 10% of new elective patients listed for liver transplantation, 
died or had to be removed from the list. 
 
The three monthly reviews of the National Liver Offering Scheme (NLOS) introduced in March 2018 for brain 
death donor (DBD) organs based on a possible transplant benefit score at five years, showed a fall in the median 
waiting time for transplantation to 39 from 72 days but the acceptance rate of offers made through the scheme to 
specific matched recipients was lower than predicted at 30%. This has been accompanied by an increase (8% to 
28%) of DBD livers not accepted for named recipients. New patients added to the waiting list since the inception 
of the scheme are more likely to be transplanted and as predicted by the modelling exercise, there is an undesirable 
trend towards older patients being transplanted and a reduction in those with HCC.  
 
Results of the soft version, opt-out legislation introduced in Wales in 2018 are also disappointing with no increase 
in number of donor organs, though there has been an increase in donor consent rates by families which are now 
exceed those in England. With the implementation shortly of opt-out in England in spring 2020 and a wider uptake 
of organ perfusion strategies in increasing organ utilisation, the opportunity would be taken to tackle unmet needs 
for liver transplantation such as service evaluations on chronic liver failure, hilar cholangiocarcinoma and 
neuroendocrine tumours, but as yet no definite  proposals have been agreed. 
 
Currently there is no approval for additional liver transplant centres to increase transplant capacity. NHSE are 
allowing consideration of aspirant market entrants to replace or add to the existing providers. A number of aspirant 
centres including Plymouth, Oxford and Liverpool are working towards this but none are as yet in place and 
although it is difficult to us the term failure when overall results of transplant procedures are so good (96-97% 
one year survival) nevertheless the demand is not being met as it could be. 
 
Major Vacancies in Workforce of Consultant Hepatologists and Specialist Nurses 
The goal for an effective specialist hepatobiliary service is to have two hepatologists serving 250,000 people or 
0·8 whole time equivalent (WTE) per 100,000 population. Based on recent (2017) estimates, 221 hepatologists or 
306 gastroenterologists with an interest in Hepatology are leading these services although the number is variable 
across the UK, with Scotland, England, Northern Ireland and Wales having 0·39, 0·35, 0·22 and 0·08 
hepatologists respectively per 100,000 population. Optimising levels of consultant Hepatologists requires an 
increase to 528 WTE, equivalent to 222 more posts. For this, liver appointments (and funding) will need to be 
prioritised and the rate of consultant expansion improved beyond the 1·6% - 4·9% annually for gastroenterology 
in the past decade. There are also concerns about the number of transplant surgeons that will be needed to expand 
capacity of existing and new programmes, with availability of a greater number of donor organs.  
For more than a decade speciality training and accreditation in hepatology has lagged behind that for 
Gastroenterology. The ratio of specialist trainees in Hepatology to luminal gastroenterology trainees should, it is 
recommended, be increased from the current 1 in 3 ratio, thereby enabling NHS Trusts to prioritise the filling of 
vacant posts. Even wider variation exists across UK in the number of liver nurse specialists whose remit needs to 
be expanded to include day-case paracentesis and transient elastography (TE) services at the interface of primary 
and secondary care. 
Detection of Early Disease by Screening in Primary and Community Care 
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The online toolkit for GPs (73), co-ordinated by the Royal College of General Practitioners (RCGP) and funded 
by the British Liver Trust (BLT), continues to evolve with the recent addition of detailed GP commissioning 
recommendations for decision makers. It also includes, as highlighted in a national GP practice mailout, easily 
accessible information on latest national guidelines for interpretation of liver blood tests(74) and for use of 
transient elastography (Fibroscan) or Enhanced Liver Fibrosis (ELF) measurement of fibrosis based on AUDIT 
scores. The updated toolkit also includes ‘quick link’ buttons for easy access to guidelines/tools during GP 
consultations. Incentivising evidence-based care based on quality improvements, along with working with newly 
formed GP Primary Care Networks (PCNs) and their access to central funding for social and lifestyle prescribing 
represent further strong recommendations by the Commission.     
 
Inclusion of the early detection programme in an updated NHS Health Check  in line with NICE guideline NG50 
Current Advice (10) will add significantly to the value of these checks. Exemplar proven models of care include 
the prizewinning Scarred Liver Project in Nottingham and the Southampton pilot pathway region-wide is leading 
to a reduction in hepatology referrals as well (http://www.stmaryssurgery.nhs.uk/info.aspx?p=10). These need 
to be rolled out more widely in an effective context across the country as does the Tayside programme of 
Intelligent Liver Blood Tests (ILFTs) which, when increased serum transaminase or other abnormalities are 
found, also test for a raft of likely causes with the most likely diagnosis being fed back directly to the requesting 
GP (75).  
 
 
Box 2:  The Scarred Liver Project, Nottingham 
 
The Nottingham pathway continues to attract significant numbers of referrals (>3000, since inception) with 
diagnosis of significant liver disease (>20%, TE >8kPa, ~10% cirrhosis). The pathway has evolved to allow GPs 
and patients greater access to transient elastography based on risk factors alone. Any patient with type 2 diabetes, 
obesity, incidental fatty liver on ultrasound and a BARD score >1, or alcohol excess, can now go straight to 
transient elastography without the need for prior liver blood tests. Supported by the local Academic Health 
Sciences Network (AHSN), the pathway has been adapted for trials in other areas included within community 
drug and alcohol services in Chesterfield and within a regional primary care ‘super-practice’ (served population 
200k). The forward focus is on developing the brief lifestyle advice provided to all patients into a more supportive 
and sustainable behaviour change intervention.   https://www.scarredliverproject.org.uk/ (76) 
 
 
 
Each of the successful local schemes for earlier diagnosis have led to a reduction in unnecessary referrals to 
hospital-based consultant clinics with consequent cost savings. Demonstrating the effects on survival and state of 
health will require larger cohorts and longer periods of follow-up. 
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Combination of Potential Risk Factors for Liver Disease in a Primary Care Sample  
With the proven evidence of a supra-additive, synergistic interaction between raised body mass index (BMI) and 
alcohol consumption in the development of liver disease(77), knowledge of the co-occurrence of both factors is 
of considerable relevance to health screening and public health policies. The Health Improvement Network 
(THIN), a large, representative database covering anonymised electronic medical records from over 700 general 
practices,  was used to identify the occurrence of higher risk drinking, raised BMI, and both risks, in an adult 
sample attending a GP appointment in the financial year 2017/18 (personal communication, Clive Henn). Over 
50,000 patients were identified who could benefit from a brief AUDIT and 1,500 patients were both obese and 
drinking at high risk levels. True levels were thought to be substantially higher. Such individuals, with their 
substantially increased risk of liver disease, should be prioritised for screening and management measures. 
 
Outcomes in Children with Liver Disease  
Death has become a rare outcome with mortality as low as 5% and is mainly in patients who were not candidates 
for liver transplantation or as a result of untreatable complications developing in later years after transplantation. 
An audit of all deaths occurring within the three UK paediatric liver centres (PLC) over the last five years (2014-
2018) identified 137 deaths of whom 28 had undergone liver transplantation.  Only four died of conditions 
unrelated to their liver disease. 76 of the 137 deaths were unexpected and such deaths remain a significant 
organizational issue, with 54% of deaths occurring outside the centres. It is recommended that all patients 
attending the three specialist centres should be reviewed for risk of death in childhood, allowing more focused 
treatment measures as well as palliative care to be planned.  
 
Poor Neurocognitive Ability  
Although patient and graft survival continue to be excellent, poorer cognitive ability, inferior educational 
achievement and employment outcome compared to peers has become a major, emerging concern. In a systematic 
review, 67% of children with liver disease and 82% of children following liver transplantation (LT) showed low 
average or abnormal scores on specific subscales of cognitive and behavioural measures (78). Whereas neuro-
development is negatively affected by longer duration of the disease and waitlist time, it has been suggested that 
Box 3: Hepatology vs community-based referrals in Southampton Primary Liver Care Pathway, 2015-
2019 
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LT does not correct the impairment (79, 80). In addition, overall health related quality of life is inferior, and 
prevalence of mental health problems, in particular in adolescents and young adults is higher compared to the 
general population(81, 82). Lower educational attainment and special educational needs, present in 42% of 
paediatric LT survivors, are likely to impact on the development of self-management skills, including adherence 
to treatment, typically expected in an adult healthcare setting. Consequent on this employment, regarded as a 
health outcome, is inferior compared to the general population (Table 2). More attention, the Commission 
recommends, needs to be given to the concept of ‘meaningful’ survival - a state of complete physical, mental, and 
social well-being and not merely the absence of disease. 
 
 
Table 2: Employment outcome in paediatric liver transplant recipients (data from Kings College Hospital, 
London only)  
 
 Employed 
 
Unemployed  
 
In education 
Paediatric liver transplant recipients (n=100)  35% 26% 39% 
Paediatric liver transplant recipients >21 years (n=69)  46% 26% 28% 
 
Latest Situation in the Four Nations 
Minimum Unit Price for alcohol at 50pence per UK unit (10mls/8g) was introduced in Scotland on 1st May 2018 
and NHS Health Scotland has published sales data for 2018, covering four months pre- and 8 months post MUP.  
Annual sales per adult at 9.9 litres pure alcohol(6) are now at the lowest level since the data series began in 1994. 
In 2016, per adult sales in Scotland were 17% higher than in England and Wales whereas in 2018 this gap had 
narrowed to 9%. A continuing issue is that sales data for Scotland, as with the rest of the UK, is not comprehensive 
with some retailers - including the discount supermarkets - not submitting data to market research firms. Scottish 
Health Action on Alcohol Problems (SHAAP) has called for a system where there is a legal requirement for sales 
data to be provided. Published annual mortality data for 2018 (83) showed a 1% increase in all alcohol specific 
deaths with the 3% reduction in alcohol sales. The 2019 mortality data which will become available in mid-2020, 
would be expected to have fallen.  Zhao and colleagues working with Canadian data estimated that the full effect 
of price increases on mortality are seen after 3 years(84). 
 
With the early identification of liver fibrosis fundamental to reducing progression of cirrhosis, the Scottish 
Government has adopted the Tayside piloted “intelligent LFT system” (iLFT) referred to earlier which is now 
being rolled out across Scotland.  
 
In Wales, implementation of legislation for Minimum Unit Price has been delayed due to an objection made to 
the European Commission by Portugal and the plan is to introduce it in early 2020. The Irish Republic has passed 
a comprehensive alcohol Bill (85) including marketing restrictions and MUP but no implementation date has been 
set and new legislation in Northern Ireland is not expected until devolved Government is re-established. 
 
Conclusions 
The underlying aim of the present report is to emphasise yet again the important areas that need to be tackled with 
the continuing rise in health burden from liver disease consequent on lifestyle issues of excess alcohol 
consumption and obesity,  The report again stresses the present need for fiscal regulatory measures by Government 
if excessive consumption of alcohol and food is to be reduced and lives saved. The first results of introduction of 
MUP in Scotland confirm how specifically targeted the MUP is on heavy drinkers, with a dramatic decrease in 
sales of high strength low cost alcohol products and the value of the alcohol duty escalator was shown previously 
over a 5 year period. The latest report of Russia’s alcohol policy, with improvements in survival expectations, is 
evidence of the effectiveness fiscal measures targeting price, availability and marketing, in reducing consumption 
in a country(86). The finding that the levy on the sugar content of drinks is giving less than half the anticipated 
revenue to the Exchequer because of reformulation of products by the industry, shows also what is achievable by 
fiscal initiatives.  
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In the Commission’s view, without these measures the chances of achieving 5 extra years of healthy living, as 
targeted by the Secretary of State for Health and Social Care, is very unlikely. Furthermore, with the extraordinary 
lack of awareness of liver disease by the public shown in the new ComRes survey, putting the entire responsibility 
on the individual to control lifestyle excesses, as recommended in the Government’s recently published Prevention 
Green paper, is unlikely to be successful in comparison with the population directed regulatory initiatives 
described.  
 
The latest unacceptably high e mortality figures given in the report for severely ill liver patients admitted to DGHs 
is an urgent reminder of the need for NHSE to implement the masterplan for hospital services based on regional 
specialist centres, each linked to networks of DGHs through operational delivery networks (ODNs). Along with 
this is the wider use of discharge care bundles for guiding further treatment on an outpatient basis and reducing 
the high hospital readmission rates. The effectiveness of a number of locally driven schemes based on availability 
of elastography also shows a way forward for the earlier detection of liver disease in general practice. Introduction 
of appropriate financial incentives for its inclusion as part of the Health Check would ensure wider uptake and is 
strongly endorsed by the Commission. 
 
Finally, the financial appraisals by the Commission show how costly the health burden is to the country and the 
savings to the Revenue that would be obtained from the fiscal measures suggested, should be a powerful influence 
too in getting recommendations accepted by the higher echelons of Government. 
 
 
Box 4: The Commission’s Key Messages and Priorities for 2019-20 
 
Key Messages:- 
 There is a further increase in the disease burden from excess alcohol consumption and overweight/obesity  
 The mortality for acutely sick liver patients admitted to District General Hospitals is unacceptably high 
 An early detection programme in general practice based on elastography is a feasible and logical 
proposition  
 The public awareness of liver health hazards is extraordinarily poor as shown in the new  ComRes poll 
Key Priorities:- 
 Convincing upper echelons of Government of the need for fiscal regulatory measures including MUP, 
tax duty escalator and levy on food content 
 Implementation by NHS of Masterplan for hospitals and day-care treatments based on specific guideline 
bundles 
 Further investigation into causes of cognitive impairment and consideration of  meaningful survival in 
paediatric liver disease  
 Widening the impact of expert opinion on the present burden of liver disease through greater coordination 
with the Academy of Medical Sciences, the Royal Colleges and Royal Society of London 
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